"This restructure reflects the strengthening commitment and confidence of Benitec's major shareholder, Nant Capital'
A month after this statement came the Axovant deal and then the chairman's presentation in November. The narrative of the company conducting a strategic realignment of its clinical pipeline and business model is very much intact. There is a delay is the finalization of the pipeline but I would suggest it will be worth the wait.
Good luck all holders.
BLT Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held